C - Chemistry – Metallurgy – 07 – F
Patent
C - Chemistry, Metallurgy
07
F
C07F 9/6561 (2006.01) A61K 31/675 (2006.01) A61P 31/18 (2006.01)
Patent
CA 2687647
The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.
La présente invention porte sur une nouvelle forme cristalline de Tenofovir disoproxil fumarate (Tenofovir DF), désignée comme co-cristaux TDFA 2:1, sur des procédés permettant de les préparer et sur leur utilisation dans des applications pharmaceutiques, en particulier dans des médicaments anti-VIH. La forme cristalline TDFA 2:1 peut être utilisée en combinaison avec d'autres médicaments anti-VIH, tels que l'Efavirenz, l'Emtricitabine, le Ritonavir et/ou TMC114.
Anker Johnny
Dova Evanthia
Mazurek Jaroslaw Marek
Ridout & Maybee Llp
Ultimorphix Technologies B.v.
LandOfFree
Tenofovir disoproxil hemi-fumaric acid co-crystal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tenofovir disoproxil hemi-fumaric acid co-crystal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tenofovir disoproxil hemi-fumaric acid co-crystal will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1911720